Therefore, we predict that mutations at the amino terminus of KMT2C and KMT2D SET domains (Supplementary Table S3) might result in the truncation of the SET domain or loss of function of KMT2C and/or KMT2D methyltransferases, subsequently contributing to breast cancer initiation and progression. Here, KMT2D is linked to breast carcinoma.